Michal Tomasz Marzec

CV

Date of birth: June 2, 1973, Wroclaw, Poland, married, two children

Education:   

2011  Ph.D.    Medical University of Bialystok, advisor prof. R. Bucki

2000  M.D.    Medical University of Warsaw

Research Experience:   

• 2019: Associate Professor, Department of Biomedical Sciences, University of Copenhagen
• 2015-2018: Assistant Professor, Department of Biomedical Sciences, University of Copenhagen
• 2010-2014: Research Associate II, Cell and Molecular Biology, Abramson Pediatric Research Center, Children’s Hospital of Philadelphia, USA
• 2006-2009:Research Associate, Cancer Biology, University of Pennsylvania, USA
• 2001-2006: Visiting Scholar, Cancer Biology, University of Pennsylvania, USA

Grants (Principal Investigator):  

2018              Augustinus Fonden

2018              Private Foundations for purchase of lab equipment (OMIX application)

2018              DFF FTP Project 1 (Prof. Gourdon PI)

2017              ERC Starting grant 2^nd round, not founded

2017-2018     EFSD/Lilly Programme

2017              Vissing Fonden

2017              Bjarne Jensen Fonden

2017              Poul og Erna Sehested Hansens Fond

2017              Eva og Hans Carl Holms Mindelegat

2016-2017     Kirsten og Freddy Johansens Fond

2016              A.P. Møller Fond

2016              Dagmar Marshall Fond

2015-2016     Augustinus Fonden

2015-2017     DFF Marie Curie Mobilex

2011-2016     National Institute on Aging, NIH

2011-2013     CTRC Junior Investigator Pilot Grant Program University of Pennsylvania and Children’s Hospital of Philadelphia

Biometrics:

H-index: 21 (Google scholar, Scopus)

i10-index: 24 (Google scholar)

Citations: 1950 (Google scholar), 1430 (Scopus)

Research Publications, peer reviewed: 30, 1 as a senior author, 13 as the first author

Teaching and Supervision

At UCPH:

• Male and female reproductive systems for non-medical students. Lectures during 2018.
• Sygdomslære for ikke-klinikere, Sundhed og Informatik, Kvantitativ biologi og sygdomsmodellering courses since 2017.
• Kursus i medicinsk fysiologi og patofysiologi Odontology since 2018.
• The main supervisor for PhD, six Master students (UCPH), one ERASMUS Master student and four BA students (UCPH, U. of California and U. of Michigan, USA)

At USA:        

• I have daily supervised Master students as well as trained technicians

Pedagogical competences

Universitetspædagogikum (Higher Education) course 2017 at UCPH

Postdoctoral Research Leadership Course, May 2015 at Copenhagen Business School

Laboratory Animal Science Course, March 2015 at UCPH

Collaborations:

Prof. Marie-Pierre Bousquet, Toulouse, France

Prof. Peter Arvan U. of Michigan, USA

Prof. Anders Tengholm Uppsala University, Sweden

Prof. Sebastian Barg Uppsala University, Sweden

Prof. J. V. Rocheleau U. of Toronto, Canada

Prof. Bu Yeap U. of Western Australia, Australia

Prof. Pontus E. Gourdon UCPH, Denmark

Prof. Per A. Pedersen UCPH, Denmark

Prof. Soren Buus UCPH, Denmark

Prof. Flemming Pociot Herlev-Gentofte Hospital, Denmark

Meetings organizing:               

• 2017    BioFrontiers Summit, University of Copenhagen
• 2016    “Single pancreatic islet transduction using HEAT-on-Chip device” Workshop. University of Copenhagen

Invited Lectures:                                   

• 2018; 'Proinsulin processing and endoplasmic reticulum chaperones' Islet Study Group meeting, Potchdam 2018
• 2018: “How do proinsulin peptides become immunogenic“ EFSD, Lilly, Research grant program, Dresden, Germany
• 2013: “Variations in GRP94 gene in human centenarians’ populations” Gordon Research Conference Insulin-Like Growth Factors in Physiology & Disease; Ventura CA
• 2012: “Regulation of IGF-1 by Human GRP94” National Institute on Aging, NIH Bethesda Sixth Annual Division of Aging Biology New Investigators Forum
• 2009: “NPM/ALK mimics IL-2 type signaling in CD4+ T cells” University of Pennsylvania, Philadelphia, PA November 2009

Awards:                                                  

2013              IGF Society Award

2006              Medical University of Warsaw President’s award for research on B cell lymphomas 

Professional Services:                                                                         

Reviewer for Polish Ministry of Science and Higher Education

Reviewer for the journal of Blood, Laboratory Investigation, Leukemia, Oncogene                                                                

Memberships in Professional and Scientific Societies:

2016              Danish Society for Immunology

2016              European Association for the Study of Diabetes

2014              Danish Diabetes Academy

2013              Penn/CHOP Center for Orphan Disease Research and Therapy

2013              International Society for IGF Research

2005              American Society of Cell Biology

2000              The Polish Chamber of Physicians and Dentists

Symposia and Abstracts (2012-2018):             

• October, 2017: “The role of GRP94 chaperone in proinsulin processing“ NovoNordisk Conference, Denmark
• May, 2017: “The role of GRP94 chaperone in proinsulin processing“ Beta Cell Workshop, Dresden, Germany
• May, 2016: “The role of GRP94 chaperone in proinsulin processing“  EASD 52nd Annual meeting, Munch, Germany
• May, 2015: “GRP94 as a regulator of insulin and IGF production“  The EASD Study Group on Genetics of Diabetes  Krakow, Poland
• Nov, 2013: “Modulation of maturation and secretion of IGF-1 and -2 by genetic variants of GRP94 found in human populations” Copenhagen, Denmark “Genomics in Metabolism” 4th Copenhagen Bioscience Conference
• July, 2012: “Hypomorphic variants of human GRP94 affect the production of circulating IGF-1” Bregenz, Austria The 11th International Symposium on Neurobiology and Neuroendocrinology of Aging
• Feb, 2012: “IGF and human GRP94” GRC meeting Biology of Aging; Ventura CA

Publications:

1. S.M. Ghiasi, T. Dahlby, C.H. Andersen, L. Haataja, S. Pedersen, M.O. Hmeadi, M. Yang, C. Pihl, S. Bresson, M. Khilji, K. Klindt, O. Cheta, M. J. Perone, B.Tyrberg, C. Prats, S. Barg, A. Tengholm, P. Arvan, T. Mandrup-Poulsen, M. Marzec. The role of GRP94 chaperone in proinsulin handling. Diabetes 2019, in press. IF: 8.6

2. M. Marzec Students’ supervision and introduction during the initial period in the research laboratory: does it matter? Improving university Science Teaching and Learnig, Vol. 12 p. 107 2018               

3. M. Wątek, B. Durnaś, T. Wollny, M. Pasiarski, S. Góźdź, M. Marzec, A. Chabowska, P. Wolak, M. Żendzian-Piotrowska, R.Bucki. Unexpected profile of sphingolipid contents in blood and bone marrow plasma collected from patients diagnosed with acute myeloid leukemia. Lipids in Health and Disease. 16:235 2017 IF: 2

4. M. Marzec, CP. Hawkes, D. Eletto, S. Boyle, R. Rosenfeld and V. Hwa, J-M. Wit, H A. van Duyvenvoorde, W. Oostdijk, M. Losekoot, LuCamp, BB. Yeap, L. Flicker, G. Atzmon, N. Barzilai, A. Grimberg, Y. Argon. A human variant of GRP94 that supports IGF production inefficiently. Endocrinology 2016. IF: 4.3

5. Durnaś B, Wątek M, Wollny T, Niemirowicz K, Marzec M, Bucki R, Góźdź S. "Utility of blood procalcitonin concentration in the management of cancer patients with infections" OncoTargets and Therapy, Dec 2015. IF: 2.3

6. Urszula Surel, Katarzyna Niemirowicz, Marzec M, Paul B. Savage and Robert Bucki. 2014 Ceragenins – a new promise to fight multidrug resistant bacterial infections. Studia Medyczne UJK  30 (3): 207–213 Review

7. Marzec M, Liu X, Halasa K, Zhang Q, Odum N, Wasik MA. 2013. Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming. J.of Immunology Vol.191 (12) p.6200-7. IF: 4.9

8. Lee SC, Marzec M, Liu X, Wehrli S, Kantekure K, Ragunath PN, Nelson DS, Delikatny EJ, Glickson JD, Wasik MA. 2013. Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma. NMR Biomed. Vol.26 p.106-14 IF: 3

9. Marzec M, Eletto D, Argon Y. 2012. GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum. Biochim Biophys Acta. Vol. 1823(3) p.774-787. IF: 4.9 Cited: 175

10. Lee SC, Arias-Mendoza F, Poptani H, Delikatny EJ, Wasik M, Marzec M, Schuster SJ, Nasta SD, Svoboda J, O'Connor OA, Smith MR, Glickson JD. 2012. Prediction and Early Detection of Response by NMR Spectroscopy and Imaging. PET Clin. Vol.7 p.119-26 IF: 1

11. Marzec M, Liu X, Wysocka M, Rook AH, Odum N, Wasik MA. 2011. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells. PloS One. Vol. 6(9) e.24849 IF: 2.8

12. Marzec M, Xiaobin Liu, Waihay Wong, Yusong Yang, Theresa Pasha, Kanchan Kantekure, Paul Zhang, Anders Woetmann, Mangeng Cheng, Niels Odum, and Mariusz A. Wasik. 2011. Oncogenic kinase NPM/ALK induces through STAT3 expression of HIF1a. Oncogene. Vol. 30(11) p. 1372-8 IF: 8.4

13. Robert Bucki, Alina Kułakowska, Fitzroy J. Byfield, Małgorzata Żendzian-Piotrowska, Marcin Baranowski, M. Marzec, Jessamine P. Winer, Nicholas J. Ciccarelli, Jan Górski, Wiesław Drozdowski, Robert Bittman and Paul A. Janmey.  2010. Plasma gelsolin modulates cellular response to sphingosine 1-phosphate Am J Physiol Cell Physiology. Vol.299 p.1516-23 IF: 2.3

14. M El-Salem, PN Raghunath, M Marzec, M Kasprzycka, X Liu,  M A Wasik.  2009. Activation of mTORC1 signaling pathway in AIDS-related lymphomas (ARL). American Journal of Pathology. Vol.175 p.817-24 IF: 4.2

15. MA Wasik, Q Zhang, M Marzec, M Kasprzycka, HY Wang, X Liu.  2009. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. Sem. Oncology. Vol.36 p.27-35 IF: 6.2

16. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA, Wasik MA. 2008. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. Vol. 105(52) p.20852-7 IF: 9.6 Cited: 344

17. Kasprzycka M, Zhang Q, Witkiewicz A, Marzec M, Potoczek M, Liu X, Wang HY, Milone M, Basu S, Mauger J, Choi JK, Abrams JT, Hou JS, Rook AH, Vonderheid E, Woetmann A, Odum N, Wasik MA. 2008. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunology. Vol. 181 p.2506-12 IF: 4.9

18. Marzec M, K Halasa, M Kasprzycka, JS Yoon, X Liu, JW Tobias, D Baldwin,  Q Zhang, N Odum, AH Rook, MA Wasik. 2008. Differential effects of IL-2 and IL-15 vs. IL-21 on malignant CD4+ T lymphocytes. Cancer Research Vol. 68 p.1083-91 IF: 9.3

19. Marzec M, Xiaobin Liu, M. Kasprzycka, A. Witkiewicz, Puthiaveetil Raghunath, Mouna El-Salem, Erle Robertson, Niels Odum, Mariusz A. Wasik 2008. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood. Vol. 111 p.2181-9 IF: 13.1

20. Marzec M, M Kasprzycka, X Liu, M El-Salem, K Halasa, PN Raghunath, R Bucki, P Wlodarski, MA Wasik. 2007. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene. Vol. 26 p. 5606-14 IF: 8.4

21. P Wlodarski, X Liu, Q Zhang, M Kasprzycka, M Marzec, and M A Wasik. 2007. PU.1 regulates transcription of SHP-1 in hematopoietic cells. JBC. Vol. 282 p.6316-23 IF: 4.1

22. M El-Salem, PN Raghunath, M Marzec, P Wlodarski,  E Hsi, MA Wasik. 2007. Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders (PTLDs). Lab Investigation.Vol.87 p.29-39 IF: 4.8

23. S-H Jo, C Yang, Q Miao, M Marzec, MA Wasik, P Lu, YL Wang. 2006. PPARg promotes lymphocyte survival through its actions on cellular metabolic activities. J Immunology. Vol.177 p.3737-45 IF: 4.9

24. Marzec M, Monika Kasprzycka, Xiaobin Liu, Raghunath PN, Pawel Wlodarski, Mariusz A. Wasik. 2006. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene. Vol. 26 p.813-21 IF: 8.4

25. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA. 2006. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. 2006. Proc Natl Acad Sci U S A. Vol. 103 p.9964-9 IF: 9.6 Cited: 135

26. Marzec M, Monika Kasprzycka, Raymond Lai, Andrew Gladden, Pawel Wlodarski, Ewa Tomczak, Peter Nowell, Samuel E. DePrimo, Seth Sadis, Stephen Eck, Stephen J. Schuster, J. Alan Diehl, Mariusz A. Wasik. 2006. Mantle cell lymphoma cells express predominantly Cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood. Vol. 108 p.1744-50 IF: 13.1 Cited: 118

27. Kasprzycka M, Majewski M, Wang ZJ, Ptasznik A, Wysocka M, Zhang Q, Marzec M, Gimotty P, Crompton MR, Wasik MA. 2006. Expression and Oncogenic Role of Brk (PTK6/Sik) Protein Tyrosine Kinase in Lymphocytes. Am J Pathology. Vol. 168 p.1631-41 IF: 4.2

28. Nagasawa   T, Zhang Q, Raghunath PN, Wong HY, El-Salem M, Szallasi A, Marzec M, Gimotty P, Rook AH, Vonderheid EC, Odum N, Wasik MA. 2005. Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing. Leukemia Res. Vol. 30 p.303-12 2.3

29. Marzec M, Kasprzycka M, Ptasznik A, Wlodarski P, Zhang Q, Odum N, Wasik  MA. 2005. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Investigation. Vol. 85 p.1544-54 IF: 4.8

30. Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A, Wasik MA. 2005. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Research. Vol. 65 p. 7800-8 IF: 9.3

31. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA. 2005. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A. Vol. 102 p. 6948-53 IF: 9.6 Cited: 204

Kort præsentation

Michal Marzec graduated as MD from the Medical University of Warsaw in 2000 and took his PhD in 2011 from the University of Bialystok. He was a visiting scholar and later Research Associate at the Department of Pathology and Laboratory Medicine at the University of Pennsylvania, USA (2001-2010).

He subsequently moved to the Abramson Pediatric Research Centre, Children’s Hospital, Pennsylvania, where within his 5 year NIH K01 grant he investigated the role of endoplasmic reticulum chaperones and their human variants in the context of hormone production.

Dr. Marzec has published 31 scientific publications of which 30 are original papers in high impact peer-reviewed international journals including PNAS, Blood, Oncogene, Cancer Res, J Immunol and J Biol Chem, 1 as a senior author, 11 as 1st author. He has an H-index of 21; total citations: 1950; citations since 2014: 1000.

During his stay in USA, he designed projects independently and actively helped in writing grants. He took an active part in teaching and advising students. Dr. Marzec has lectured regularly in the USA on his research, and is a regular reviewer for the top journals in his field (Blood, Lab Invest, Leukaemia, Oncogene).

Primære forskningsområder

Over the years, Michal's research interest has shifted from understanding oncogenic pathways to providing answers to why and how organisms differ in their susceptibility to diseases. Recent massive sequencing of thousands of individuals made it possible to study the impact of human variations on pathological processes underlying multiple diseases. He joined prof. Argon’s laboratory, to work on the involvement of GRP94 in the maturation and secretion of IGF molecules. Subsequently, he described the first human variant of GRP94 and its role in the pathogenesis of Primary IGF Deficiency.

Currently he is applying his expertise into diabetes pathology where he is investigating the role of endoplasmic reticulum chaperones in proinsulin folding. In addition he is exploring the possible link between population genetic variability of protein chaperones and the susceptibility to diabetes.